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Abstract
The Mediterranean diet (MD) is a well-established and highly-studied diet that
has been recommended by the medical field for decades; however, with the
current obesity epidemic intensifying each year, it is imperative that other
options are brought forth for those who might require a more intense initial
regimen, or for those who may not be able to process the high carbohydrate load
in MDs.
Ketogenic diets (KD) have been shown to be highly effective in causing significant
weight loss and have also shown promising results in the reduction of
cardiovascular disease (CVD) risk factors. This study will explore the
improvement of CVD risk factors of obese adults on a KD compared to a MD.
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As of 2018, the Centers for Disease Control and Prevention found that just over 
42% of US citizens are estimated to be obese (BMI > 30.0.) This has 
consequences, as in 2017 alone, 4.7 million people died worldwide due to 
conditions that are strongly linked to obesity, such as heart disease, stroke, 
diabetes, and various cancers. 
The MD is one well-studied option to reduce and maintain a healthy weight and 
improve cardiovascular profiles. This diet encourages the consumption of fruits, 
vegetables, whole grains, healthy fats, fish, poultry, legumes, and eggs, while 
limiting red meat consumption. Many clinicians believe that this is a good option 
for most individuals to follow; however, the high carbohydrate content may be 
unfavorable for patients with metabolic syndrome or CVD. 
KDs may be another beneficial option for those looking to lose weight. They 
encourage approximately 70% of calories come from fat, with the remainder 
from protein with <50g daily of carbohydrates. If done correctly, this regimen 
triggers the body to enter a state of catabolism, breaking down body fat into 
ketones via ketogenesis while sparing muscle. Initial studies have indicated that 
KDs rapidly improve CVD risk factors, which could play a huge role in mitigating 
the morbidity of obesity if applied on a population level.
Introduction
Methods
Several literature searches were conducted through PubMed in November 2019 
and another through Academic Search Premier in July 2020. Six articles were 
selected that involved KDs, including randomized control trials, a prospective 
cohort study, and observational clinical trials. A final article was chosen for its in-
depth analysis of MDs. The articles were selected by publication date, cohort 
population, and relevance.
While the data from the six KD studies demonstrated more impressive  
reductions in body weight and CVD risk factors than the MD trials, there are 
many problems with the KD studies.
Compared to the MD trials, which had high statistical power due to their large 
randomized trials that took place over the span of years, there were many 
weaknesses in the KD experiments, including inferior study designs, few 
participants, short study duration, and varied procedures among KDs.
DiscussionResults
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The Impact of a Ketogenic Diet vs the Mediterranean Diet on 
Cardiovascular Disease Risk Factors of Obese Adults
For decades, the MD has been the recommendation of choice for weight 
maintenance and CVD risk reduction and should remain so for the foreseeable 
future. 
While patients may potentially benefit from a more intensive weight loss 
regimen like the KD, the current data is too weak to recommend it over the MD. 
Despite its flaws, the preliminary data collected involving reduction in CVD risk 
factors are encouraging and may inspire more wide-spread, rigorous protocols 
involving the KD in the future.
Conclusion
All six KD studies demonstrated a statistically significant decrease in 
body weight, ranging from approximately 10 to 20 kg on average. 
This is significantly more than participants in MD trials from the 
systematic review, with total weight loss decreasing approximately 
1 kg. 
There was also a significant decrease in systolic blood pressure 
(SBP) in the four KD studies that analyzed it, ranging from a 7 
mmHg to 16.7 mmHg average decrease. In the MD trials, SBP 
decreased an average of 3 mmHg.
There were also statistically significant improvements in visceral 
adipose, lipid profile, and blood glucose among the various KD 
protocols; however, several parameters of quality were inadequate. 
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Key: S = Statistically significant; NS = Not statistically significant; - = Results not available; P ≤ 0.05
BW
S = BW 
decrease of 
7+ kg 
NS = Decrease 
<7 kg 
VF
S = VF 
change
NS = No VF 
change
SBP
S = SBP decrease 
5+ mmHg 




S = reduction in LDL-C and 
TG with increase in HDL-C
NS = no/minor reduction in 
LDL-C and TG, or a decrease 
in HDL-C
BG
S = avg BG decreased 
10+ mg/dL
NS = avg BG 
decreased <10 
mg/dL
Table 3. Summary of Results
